secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2026-08-05T20:15:17+00:00
Accession:  0001193125-26-335150
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight Q2 revenue $33.7M, product sales down 19% YoY; withdraws 2026 guidance
------------------------------------------------------------------------------

- Product sales $27.2M (-19% YoY); LAL units 24,917; LDD units 12.
- Net loss $(12.1)M ($(0.29)/share); adjusted net loss $(4.6)M ($(0.11)/share).
- New CEO Aziz Mottiwala appointed; Alcon collaboration with up to $200M in payments.
- Next-gen Light Adjustable Technology platform announced; 2026 guidance withdrawn.
- Cash and investments $208.8M as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526335150/0001193125-26-335150-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000119312526335150/rxst-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-335150

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer